Mostrar el registro sencillo del ítem

dc.contributor.author
Pérez Mazliah, Damián Eduardo  
dc.contributor.author
Álvarez, M. G.  
dc.contributor.author
Cooley, G.  
dc.contributor.author
Lococo, B. E.  
dc.contributor.author
Bertocchi, G.  
dc.contributor.author
Petti, M.  
dc.contributor.author
Albareda, María Cecilia  
dc.contributor.author
Armenti, A. H.  
dc.contributor.author
Tarleton, R. L.  
dc.contributor.author
Laucella, Susana Adriana  
dc.contributor.author
Viotti, Rodolfo Jorge  
dc.date.available
2017-08-28T20:13:27Z  
dc.date.issued
2012-10  
dc.identifier.citation
Pérez Mazliah, Damián Eduardo; Álvarez, M. G.; Cooley, G.; Lococo, B. E.; Bertocchi, G.; et al.; Sequential combined treatment with allopurinol and benznidazole in the chronic phase of Trypanosoma cruzi infection: a pilot study; Oxford University Press; Journal of Antimicrobial Chemotherapy; 68; 2; 10-2012; 424-437  
dc.identifier.issn
0305-7453  
dc.identifier.uri
http://hdl.handle.net/11336/23180  
dc.description.abstract
Objectives: Even though the use of combined drugs has been proved to be effective in other chronic infections, assessment of combined treatment of antiparasitic drugs in human Chagas' disease has not been performed. Herein, a pilot study was conducted to evaluate the tolerance and side effects of a sequential combined treatment of two antiparasitic drugs, allopurinol and benznidazole, in the chronic phase of Trypanosoma cruzi infection. Patients and methods: Changes in total and T. cruzi-specific T and B cells were monitored during a median follow-up of 36 months. Allopurinol was administered for 3 months (600 mg/day) followed by 30 days of benznidazole (5 mg/kg/day) in 11 T. cruzi-infected subjects. Results: The combined sequential treatment of allopurinol and benznidazole was well tolerated. The levels of T. cruzi-specific antibodies significantly decreased after sequential combined treatment, as determined by conventional serology and by a multiplex assay using recombinant proteins. The frequency of T. cruzi-specific interferon-γ-producing T cells significantly increased after allopurinol treatment and decreased to background levels following benznidazole administration in a substantial proportion of subjects evaluated. The levels of total naive (CD45RA + CCR7 + CD62L+) CD4 + and CD8 + T cells were restored after allopurinol administration and maintained after completion of the combined drug protocol, along with a decrease in T cell activation in total peripheral CD4 + and CD8 + T cells. Conclusions: This pilot study shows that the combination of allopurinol and benznidazole induces significant modifications in T and B cell responses indicative of a reduction in parasite burden, and sustains the feasibility of administration of two antiparasitic drugs in the chronic phase of Chagas' disease.  
dc.format
application/pdf  
dc.language.iso
eng  
dc.publisher
Oxford University Press  
dc.rights
info:eu-repo/semantics/openAccess  
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/  
dc.subject
Chagas' Disease  
dc.subject
Trypanosomiasis  
dc.subject
Chemotherapy  
dc.subject
T Cells  
dc.subject.classification
Ética Médica  
dc.subject.classification
Ciencias de la Salud  
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD  
dc.title
Sequential combined treatment with allopurinol and benznidazole in the chronic phase of Trypanosoma cruzi infection: a pilot study  
dc.type
info:eu-repo/semantics/article  
dc.type
info:ar-repo/semantics/artículo  
dc.type
info:eu-repo/semantics/publishedVersion  
dc.date.updated
2017-08-22T21:23:32Z  
dc.identifier.eissn
1460-2091  
dc.journal.volume
68  
dc.journal.number
2  
dc.journal.pagination
424-437  
dc.journal.pais
Reino Unido  
dc.journal.ciudad
Oxford  
dc.description.fil
Fil: Pérez Mazliah, Damián Eduardo. Dirección Nacional de Instituto de Investigación. Administración Nacional de Laboratorio e Instituto de Salud. Instituto Nacional de Parasitología; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina  
dc.description.fil
Fil: Álvarez, M. G.. Provincia de Buenos Aires. Ministerio de Salud. Hospital Interzonal de Agudos "Eva Perón"; Argentina  
dc.description.fil
Fil: Cooley, G.. University of Georgia; Estados Unidos  
dc.description.fil
Fil: Lococo, B. E.. Provincia de Buenos Aires. Ministerio de Salud. Hospital Interzonal de Agudos "Eva Perón"; Argentina  
dc.description.fil
Fil: Bertocchi, G.. Provincia de Buenos Aires. Ministerio de Salud. Hospital Interzonal de Agudos "Eva Perón"; Argentina  
dc.description.fil
Fil: Petti, M.. Provincia de Buenos Aires. Ministerio de Salud. Hospital Interzonal de Agudos "Eva Perón"; Argentina  
dc.description.fil
Fil: Albareda, María Cecilia. Dirección Nacional de Instituto de Investigación. Administración Nacional de Laboratorio e Instituto de Salud. Instituto Nacional de Parasitología; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina  
dc.description.fil
Fil: Armenti, A. H.. Provincia de Buenos Aires. Ministerio de Salud. Hospital Interzonal de Agudos "Eva Perón"; Argentina  
dc.description.fil
Fil: Tarleton, R. L.. University of Georgia; Estados Unidos  
dc.description.fil
Fil: Laucella, Susana Adriana. Dirección Nacional de Instituto de Investigación. Administración Nacional de Laboratorio e Instituto de Salud. Instituto Nacional de Parasitología; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina  
dc.description.fil
Fil: Viotti, Rodolfo Jorge. Provincia de Buenos Aires. Ministerio de Salud. Hospital Interzonal de Agudos "Eva Perón"; Argentina  
dc.journal.title
Journal of Antimicrobial Chemotherapy  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://academic.oup.com/jac/article-lookup/doi/10.1093/jac/dks390  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1093/jac/dks390